

12th January 2021

- BSE Ltd
 Listing Department
 Phiroze Jeejeebhoy Towers,
 Dalal Street,
 Mumbai 400 001
- National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

 (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme
 35A Boulevard Joseph II, L-1840 Luxembourg

Dear Sir / Madam,

Sub: Intimation of Schedule of Analyst / Institutional Investor Meeting.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we give below, the schedule of analyst / institutional investor meeting with the Company:

Particular	Details		
Date and Time	Tuesday, January 12, 2021: 22.40 Hrs IST 12:10 Hrs ET 17.10 Hrs BST Wednesday January 13, 2021: 1.10 Hrs SST/HKT		
Fund / Investor Name	39th Annual J.P. Morgan Healthcare Conference		
Venue	Call		
Link to join the conference	https://jpmorgan.metameetings.net/events/healthcare21/sessions /35243-cipla-ltd/webcast?gpu_only=true&kiosk=true		

The presentation that will be made at the 39th Annual J.P. Morgan Healthcare Conference is enclosed and is also available on our website i.e. <u>www.cipla.com</u>

Thank you,

Yours faithfully, For Cipla Limited

Rajendra Chopra Company Secretary

Encl: as above

Prepared by: Juzer Masta

Cipla Ltd.



JP Morgan Healthcare Conference Umang Vohra, MD & Global CEO January 2021

DISCLAIMER

Cipla

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Established In 1935, Cipla has pioneered India's healthcare selfsufficiency with deep R&D capabilities

Cipla


H



Cipla continues to serve patients as custodian of respiratory health through innovative drug-device combinations, complex formulations and broad spectrum capabilities in injectables, oral solids amongst others

1. As per IQVIA MAT Sept'20; 2. including prescription, trade generics and consumer health business; 3. As per IntelliMax, markets other than India, US and EU for Apr'20 – Oct'20

Over the last 5 years, we have driven strong cost management, cash generation initiatives coupled with improved capital allocation policies



Cipla

1. Net Debt = Total borrowings less Cash and Cash equivalents including Current Investments; Sept-20: Net debt ÷ Annualized EBITDA 2. RoIC = EBITDA - depreciation & amortisation ÷ Average [(Fixed assets including goodwill + Current assets excluding cash and cash equivalent) - Current liabilities excluding borrowing]]; H1FY21: Calculations based on annualised EBITDA In 2020, we contributed significantly to the global cause of combating Covid-19 and deliver on our promise of 'Caring for life'

Cipla

Supporting the Government, frontline warriors and employees across geographies



- INR 25 Crore contribution to Caring for life Covid-19 dedicated fund in India
- Relief efforts for patients, frontline workers and community







• Six containers deployed for Covid-19 screening in South Africa



• Covid-19 Central task force formed with strong protocols on ensuring employee safety and un-interrupted plant operations Comprehensive Covid-19 portfolio for diagnosis and treatment



At Cipla, we are executing the blueprint for sustainable value creation for our stakeholders





Expanding lung leadership globally and maximising value opportunity in US complex generics



Maintain market-beating growth in large branded and unbranded generic franchises of India & South Africa; augment consumer wellness franchise



Focused DTMs¹ and new frontier markets (China & Brazil) for organic growth in Europe and Emerging markets; expanding biosimilar partnerships in key markets to drive future growth



Leverage digital capabilities to deliver transformative business and patient outcomes in the new normal



Focus on regulatory compliance across manufacturing locations and embrace best-in class globally benchmarked ESG² practices




Consistent upward RoIC trajectory over the long term

1. Direct-to-market; 2. Environmental, Social and Governance


We are focused on driving our US business growth through strong execution of our complex asset pipeline

Cipla

Incremental opportunity to add \$300m-\$500m to US franchise by FY25



1. Filed and under development at Sept'20 end; 2. Tentatively approved and filed at Sept'20 end



Includes all dosage forms predominantly resputes and inhalers
 under development projects at Sept'20 end

In India, we are driving smooth execution of our One India strategy

Cipla





Cipla

Initiatives to build a consistent market beating prescription growth engine



Making big brands bigger by targeting large brands to accelerate market share gains




Focused execution across therapies and productivity improvements with higher engagements and outreach



Digital adoption and GoApptiv analytics on distribution and consumption insights for actionable outcomes




Enhance portfolio breadth via inorganic or partnership route



1. Market data IQVIA MAT Sept'20







Strongly positioned trade generics & consumer businesses for improved generic access and wellness experience

India's largest trade generic business strengthening by leveraging consumer play

rics	1st India's Largest trade generic business 15,000+ pin codes serviced pan India' 5,500 Stockiest network'			Creating consumer franchise: Omnigel®		
de generics				India's #1 pain recovery gel	~675m+ people via TVC reach ²	
Trade					~50m+ people via Digital ²	19% Market share ³
	Portfolio of flagship brands that outperform market with innovative brand extensions			Strong demand in consumer brands post trans from trade generics in H1FY21		
£	Portfolio of			t with		
ealth				t with		
nsumer health	2.5x YoY growth in overall	innovative br Category • Nicotine Replacement therapy	and extensions Brands • Nicotex® Market lea Ranked 3 rd ; stra	nder ong chemist	from trade g	generics in H1FY21
Consumer health	2.5x YoY growth	innovative br Category • Nicotine Replacement	and extensions Brands • Nicotex® Market lea Ranked 3 rd ; stra	ader ong chemist esence	from trade g Category • Oral Rehydration salt • Multi-vitamin	penerics in H1FY21 Brands • Prolyte® • Maxirich®


In SAGA, we continue to maintain our strong market position in private and OTC markets

Cipla

Enhancing private market presence via organic launches and deepening footprint via MNC partnerships




1 IQVIA MAT Oct'20; Rank as per market where we play (WWP) and market share as per total private market (TPM)




2. revenue growth includes B2B and Direct to market (DTM) businesses; 3. B2B + DTM markets

Leveraging digital capabilities to transform business and patient outcomes in the new normal

Cipla






* Renamed from Medicine Control Council (MCC), South Africa

Integrated annual report with significantly enhanced levels of transparency, disclosures and sustainability

Cipla




Recognized amongst India's best governed companies at various platforms

South Asian Federation of Accountants



We are streamlining ESG initiatives to develop a holistic sustainability road map for the future

Cipla





Consistent upward RoIC trajectory over the long term

Cipla

1	Driving growth	Unlocking power of product portfolio and focused execution of priority launches	Strong governance and focused efforts on re-imagination in H1FY21		
2	Margin expansion & Cost focus	Driving sharper discipline on margin, product mix, zero basing cost, leveraging analytics and building scenarios to identify value drivers	~24% EBITDA margins (H1FY21)	Strong RoIC trajectory for FY21	
3	Capital allocation	Allocating capital towards building capabilities and creating capacities for future growth	FY16 Net cash ¹ : (\$560m)	Sept-20 Net cash positive	

Near to medium term focus on growth, CoGS and mix management across businesses



Sustainable cost reduction



Continued EBITDA margin expansion over next 2-3 years



Sustainable RoIC expansion to 17%-20% over the long term

1. Net Cash = Cash and Cash equivalents including Current Investments - Total borrowings

To recap, our priorities include

Cipla



Expanding lung leadership globally and maximising value opportunity in US complex generics

Incremental opportunity to add \$300m-\$500m by FY25

12%-15% share of consumer business and market beating growth in India & South Africa



,	generic franchises of India & South Africa; augment consumer wellness franchise	
2	Focused DTMs and new frontier markets (China & Brazil) for organic growth in Europe and Emerging markets; expanding biosimilar partnerships in key markets	

Maintain market-beating arowth in large branded and unbranded

Annualized \$375m+ business Multiple levers to drive growth



Leverage digital capabilities to deliver transformative business and patient outcomes in the new normal

Digital patient care continuum

Focus on regulatory compliance across manufacturing locations and embrace best-in class globally benchmarked ESG practices Global benchmark for quality compliance & ESG



Consistent upward RoIC trajectory over the long term

RoIC expansion to 17%-20% over the long term



Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

For any queries, please contact Naveen Bansal Investor.Relations@cipla.com

For more information please visit <u>www.cipla.com</u>